Neuphoria Therapeutics (NEUP) Goodwill (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Goodwill for 7 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Goodwill rose 4.64% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 4.64% increase from a year earlier, with the FY2025 full-year figure at $8.6 million, down 0.59% from the prior year.
• Goodwill was $8.8 million for Q1 2026 at Neuphoria Therapeutics, up from $8.7 million in the prior quarter.
• Over five years, Goodwill peaked at $9.2 million in Q2 2022 and troughed at $8.4 million in Q4 2024.
• A 5-year average of $8.7 million and a median of $8.7 million in 2024 frame the typical range for Goodwill.
• Across the five-year window, Goodwill retreated 5.12% in 2023 and climbed 4.64% in 2026, its largest moves.
• Over 5 years, Goodwill stood at $9.2 million in 2022, then slipped by 4.09% to $8.8 million in 2023, then retreated by 4.9% to $8.4 million in 2024, then gained by 3.93% to $8.7 million in 2025, then advanced by 1.21% to $8.8 million in 2026.
• The last three Goodwill figures came in at $8.8 million (Q1 2026), $8.7 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.